BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36414855)

  • 1. Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia.
    Lackner D; Geissler K
    Wien Med Wochenschr; 2023 Feb; 173(1-2):27-33. PubMed ID: 36414855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia.
    Zack MT; Geissler K
    Wien Med Wochenschr; 2023 Feb; 173(1-2):21-26. PubMed ID: 36445600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of reduced renal function in patients with chronic myelomonocytic leukemia.
    Heschl J; Geissler K
    Wien Med Wochenschr; 2023 Feb; 173(1-2):3-8. PubMed ID: 36282402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
    Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
    Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
    Palomo L; Garcia O; Arnan M; Xicoy B; Fuster F; Cabezón M; Coll R; Ademà V; Grau J; Jiménez MJ; Pomares H; Marcé S; Mallo M; Millá F; Alonso E; Sureda A; Gallardo D; Feliu E; Ribera JM; Solé F; Zamora L
    Oncotarget; 2016 Aug; 7(35):57021-57035. PubMed ID: 27486981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.
    Machherndl-Spandl S; Jäger E; Barna A; Gurbisz M; Marschon R; Graf T; Graf E; Geissler C; Hoermann G; Nösslinger T; Pfeilstöcker M; Bettelheim P; Zach O; Weltermann A; Heibl S; Thaler J; Zebisch A; Sill H; Stauder R; Webersinke G; Kusec R; Ulsperger E; Schneeweiss B; Öhler L; Germing U; Valent P; Tüchler H; Geissler K
    Eur J Haematol; 2021 Aug; 107(2):265-274. PubMed ID: 33998054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia.
    Kim HY; Lee KO; Park S; Jang JH; Jung CW; Kim SH; Kim HJ
    Ann Lab Med; 2018 Nov; 38(6):495-502. PubMed ID: 30027691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
    Moreno Berggren D; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ungerstedt J; Ejerblad E
    Br J Haematol; 2021 Feb; 192(3):474-483. PubMed ID: 32501529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myelomonocytic leukemia: myeloproliferative variant.
    Onida F; Beran M
    Curr Hematol Rep; 2004 May; 3(3):218-26. PubMed ID: 15087071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related mutations and chronic myelomonocytic leukemia.
    Mason CC; Khorashad JS; Tantravahi SK; Kelley TW; Zabriskie MS; Yan D; Pomicter AD; Reynolds KR; Eiring AM; Kronenberg Z; Sherman RL; Tyner JW; Dalley BK; Dao KH; Yandell M; Druker BJ; Gotlib J; O'Hare T; Deininger MW
    Leukemia; 2016 Apr; 30(4):906-13. PubMed ID: 26648538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
    Ouyang Y; Qiao C; Chen Y; Zhang SJ
    Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival.
    Geissler K; Jäger E; Barna A; Graf T; Graf E; Öhler L; Hoermann G; Valent P
    Eur J Haematol; 2021 May; 106(5):627-633. PubMed ID: 33432601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia.
    Weinfurtner C; Geissler K
    Wien Med Wochenschr; 2023 Feb; 173(1-2):9-14. PubMed ID: 36205826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations.
    Kipfer B; Daikeler T; Kuchen S; Hallal M; Andina N; Allam R; Bonadies N
    Semin Hematol; 2018 Oct; 55(4):242-247. PubMed ID: 30502853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.
    Zhao W; Zhang C; Li Y; Li Y; Liu Y; Sun X; Liu M; Shao R
    Hematology; 2022 Dec; 27(1):367-378. PubMed ID: 35306971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia.
    Hirsch-Ginsberg C; LeMaistre AC; Kantarjian H; Talpaz M; Cork A; Freireich EJ; Trujillo JM; Lee MS; Stass SA
    Blood; 1990 Sep; 76(6):1214-9. PubMed ID: 2205309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.
    Shou LH; Cao D; Dong XH; Fang Q; Wu Y; Zhang Y; Fei JP; Xu BL
    PLoS One; 2017; 12(2):e0171608. PubMed ID: 28158286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations.
    Gur HD; Loghavi S; Garcia-Manero G; Routbort M; Kanagal-Shamanna R; Quesada A; Khogeer H; Pierce S; Medeiros LJ; Kantarjian H; Khoury JD
    Am J Surg Pathol; 2018 Jun; 42(6):799-806. PubMed ID: 29596070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
    Lin Y; Zheng Y; Wang ZC; Wang SY
    Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients.
    Geissler K; Jäger E; Barna A; Gurbisz M; Graf T; Graf E; Nösslinger T; Pfeilstöcker M; Tüchler H; Sliwa T; Keil F; Geissler C; Heibl S; Thaler J; Machherndl-Spandl S; Zach O; Weltermann A; Bettelheim P; Stauder R; Zebisch A; Sill H; Schwarzinger I; Schneeweiss B; Öhler L; Ulsperger E; Kusec R; Germing U; Sperr WR; Knöbl P; Jäger U; Hörmann G; Valent P
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32344757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.